Standout Papers

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy... 2007 2026 2013 2019 988
  1. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial (2009)
    Philip Home, Stuart Pocock et al. The Lancet
  2. Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis (2007)
    Philip Home, Stuart Pocock et al. New England Journal of Medicine

Immediate Impact

3 from Science/Nature 118 standout
Sub-graph 1 of 16

Citing Papers

Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes
2023 Standout
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
2023 Standout
9 intermediate papers

Works of Philip Home being referenced

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3)
2015
Hypoglycemia Rates with Basal Insulin Analogs
2011
and 10 more

Author Peers

Author Last Decade Papers Cites
Philip Home 7641 3186 2489 218 10.3k
David R. Owens 6222 2699 2018 269 9.8k
George Grunberger 6718 3411 3201 160 10.5k
Stephen C. Bain 6975 3488 3414 246 11.2k
Yehuda Handelsman 6163 3192 1949 110 8.9k
J. Hans DeVries 8275 4058 1679 232 12.5k
Guntram Schernthaner 6064 2636 2851 223 10.6k
Samuel Dagogo‐Jack 6934 2564 2361 198 10.8k
Eberhard Standl 5815 2322 2049 205 8.8k
Yasuhiko Iwamoto 4756 2180 2698 267 10.2k
William C. Duckworth 7076 2931 3740 198 12.7k

All Works

Loading papers...

Rankless by CCL
2026